These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 25139195

  • 1. Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients--a randomized placebo-controlled trial.
    Faurschou A, Gyldenløve M, Rohde U, Thyssen JP, Zachariae C, Skov L, Knop FK, Vilsbøll T.
    J Eur Acad Dermatol Venereol; 2015 Mar; 29(3):555-9. PubMed ID: 25139195
    [Abstract] [Full Text] [Related]

  • 2. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI, Hooft L.
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of Adalimumab Compared With Methotrexate or Placebo Stratified by Baseline BMI in a Randomized Placebo-Controlled Trial in Patients With Psoriasis.
    Prussick R, Unnebrink K, Valdecantos WC.
    J Drugs Dermatol; 2015 Aug; 14(8):864-8. PubMed ID: 26267731
    [Abstract] [Full Text] [Related]

  • 4. Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial.
    Lin L, Xu X, Yu Y, Ye H, He X, Chen S, Chen X, Shao Z, Chen P.
    J Dermatolog Treat; 2022 May; 33(3):1428-1434. PubMed ID: 32962477
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: a systematic review and meta-analysis of prospective cohort and before-after studies.
    Chang G, Chen B, Zhang L.
    J Dermatolog Treat; 2022 May; 33(3):1299-1305. PubMed ID: 33934692
    [Abstract] [Full Text] [Related]

  • 6. Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial.
    Mok J, Adeleke MO, Brown A, Magee CG, Firman C, Makahamadze C, Jassil FC, Marvasti P, Carnemolla A, Devalia K, Fakih N, Elkalaawy M, Pucci A, Jenkinson A, Adamo M, Omar RZ, Batterham RL, Makaronidis J.
    JAMA Surg; 2023 Oct 01; 158(10):1003-1011. PubMed ID: 37494014
    [Abstract] [Full Text] [Related]

  • 7. Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study.
    Ahern T, Tobin AM, Corrigan M, Hogan A, Sweeney C, Kirby B, O'Shea D.
    J Eur Acad Dermatol Venereol; 2013 Nov 01; 27(11):1440-3. PubMed ID: 22691169
    [Abstract] [Full Text] [Related]

  • 8. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
    Lebwohl MG, Kircik L, Callis Duffin K, Pariser D, Hooper M, Wenkert D, Thompson EH, Yang J, Kricorian G, Koo J.
    J Am Acad Dermatol; 2013 Sep 01; 69(3):385-92. PubMed ID: 23643256
    [Abstract] [Full Text] [Related]

  • 9. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.
    Flint A, Kapitza C, Hindsberger C, Zdravkovic M.
    Adv Ther; 2011 Mar 01; 28(3):213-26. PubMed ID: 21340616
    [Abstract] [Full Text] [Related]

  • 10. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
    Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, Guzzo C, Patel K, Menter A, Gottlieb AB.
    Br J Dermatol; 2005 May 01; 152(5):954-60. PubMed ID: 15888152
    [Abstract] [Full Text] [Related]

  • 11. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.
    Shikiar R, Heffernan M, Langley RG, Willian MK, Okun MM, Revicki DA.
    J Dermatolog Treat; 2007 May 01; 18(1):25-31. PubMed ID: 17365264
    [Abstract] [Full Text] [Related]

  • 12. Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: A prospective cohort study.
    Xu X, Lin L, Chen P, Yu Y, Chen S, Chen X, Shao Z.
    Diabetes Res Clin Pract; 2019 Apr 01; 150():167-173. PubMed ID: 30844468
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
    Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, Haemmerle S, Thurston HJ, Papavassilis C, Richards HB.
    Br J Dermatol; 2013 Feb 01; 168(2):412-21. PubMed ID: 23106107
    [Abstract] [Full Text] [Related]

  • 14. Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials.
    Papp KA, Yang M, Sundaram M, Jarvis J, Betts KA, Bao Y, Signorovitch JE.
    Value Health; 2018 Jan 01; 21(1):1-8. PubMed ID: 29304933
    [Abstract] [Full Text] [Related]

  • 15. The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial.
    Kramer CK, Zinman B, Choi H, Connelly PW, Retnakaran R.
    J Clin Endocrinol Metab; 2015 Oct 01; 100(10):3702-9. PubMed ID: 26230296
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial.
    Igarashi A, Kato T, Kato M, Song M, Nakagawa H, Japanese Ustekinumab Study Group.
    J Dermatol; 2012 Mar 01; 39(3):242-52. PubMed ID: 21955098
    [Abstract] [Full Text] [Related]

  • 17. Etanercept treatment for children and adolescents with plaque psoriasis.
    Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I, Hebert AA, Eichenfield LF, Patel V, Creamer K, Jahreis A, Etanercept Pediatric Psoriasis Study Group.
    N Engl J Med; 2008 Jan 17; 358(3):241-51. PubMed ID: 18199863
    [Abstract] [Full Text] [Related]

  • 18. Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis.
    Mostafa NM, Nader AM, Noertersheuser P, Okun M, Awni WM.
    J Eur Acad Dermatol Venereol; 2017 Mar 17; 31(3):490-497. PubMed ID: 27545848
    [Abstract] [Full Text] [Related]

  • 19. Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab.
    Armstrong AW, Villanueva Quintero DG, Echeverría CM, Gu Y, Karunaratne M, Reyes Servín O.
    Am J Clin Dermatol; 2016 Dec 17; 17(6):691-699. PubMed ID: 27815915
    [Abstract] [Full Text] [Related]

  • 20. Effect of the glucagon-like peptide-1 analogue liraglutide versus placebo treatment on circulating proglucagon-derived peptides that mediate improvements in body weight, insulin secretion and action: A randomized controlled trial.
    Kim SH, Abbasi F, Nachmanoff C, Stefanakis K, Kumar A, Kalra B, Savjani G, Mantzoros CS.
    Diabetes Obes Metab; 2021 Feb 17; 23(2):489-498. PubMed ID: 33140542
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.